NCT03727789 - CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 1, 2019

Primary Completion Date

January 16, 2024

Study Completion Date

January 16, 2024

Conditions

Advanced Cutaneous Melanoma of the ExtremityAdvanced Sarcoma of the ExtremityClinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Pathologic Stage IIIB Cutaneous Melanoma AJCC v8Pathologic Stage IIIC Cutaneous Melanoma AJCC v8Pathologic Stage IV Cutaneous Melanoma AJCC v8Recurrent Cutaneous Melanoma of the ExtremityRecurrent Sarcoma of the ExtremityStage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8

Interventions

DRUG

FACT Complex-targeting Curaxin CBL0137

Given IA

Trial Locations (1)

14263

Roswell Park Cancer Institute, Buffalo